Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPR | P35270 | 9/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | CCR2 | P41597 | 1/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.47 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | PDE4A | P27815 | 3/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.42 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5070874 | 0.86 | SPR (0.61) | SPRPOLBCCR2CCR5LMNA | |
| SCHEMBL7553541 | 0.84 | SPR (0.60) | SPRPOLBCCR2CCR5LMNA | |
| SCHEMBL8574855 | 0.82 | SPR (0.61) | SPRPOLBCCR2CCR5LMNA | |
| SCHEMBL5961432 | 0.77 | GSK3B (0.49) | SPRPOLBPDE4APDE4BPDE4C | |
| SCHEMBL21500663 | 0.77 | SPR (0.69) | SPRPOLBLMNAKDM4EHPGD | |
| SCHEMBL5069154 | 0.76 | SPR (0.52) | SPRPOLBCCR2CCR5LMNA | |
| SCHEMBL20413616 | 0.76 | SPR (0.59) | SPRPOLBCCR2CCR5HPGD | |
| SCHEMBL17963352 | 0.76 | SPR (0.53) | SPRKDM4E | |
| SCHEMBL14430228 | 0.75 | SPR (0.52) | SPRPOLBCCR2CCR5PIM3 | |
| SCHEMBL3353659 | 0.75 | SPR (0.46) | SPRPOLBCCR2CCR5PIM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6992086-B2 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. (US) | 2006-01-31 | — | — | US | disclosed |
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | TELIK, INC. | 2004-04-22 | — | — | US | disclosed |
| US-6670364-B2 | For example (1,3-dimethylpyrazolo(5,4-b)pyridin-5-yl)-N-(((4-fluorophenyl) amino)carbonyl)-carboxamide; useful in prevention or treatment of chronic or acute inflammatory or autoimmune diseases | TELIK, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | SANWA KAGAKU KENKYUSHO CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077680-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | SPR 430/4885POLB 3248/4885CCR2 1/4885 |
| US-20030096705-A1 | Antagonists of MCP-1 function and methods of use thereof | CCR2, CCR1, CCL2 | SPR 430/4885POLB 3248/4885CCR2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.